Summary of Wanchen Group (A) Conference Call Company Overview - **Company**: Wanchen Group (A) - **Sector**: Supermarkets/Food Retailers - **Description**: Wanchen is one of China's fastest-growing snack and beverage retailers, transitioning from an edible-fungi producer to a national discount-retail leader, operating over 18,000 stores by 2025 [11][12] Key Financial Highlights - **2025 Performance**: - Sales increased by 59% YoY, with snack and agricultural products contributing 60% and 12% respectively to total sales [3] - Net Profit After Tax (NPAT) surged by 358% YoY [3] - Gross Profit Margin (GPM) improved by 164 basis points to 12.4% due to economies of scale [3] - Operating Profit (OP) rose by 217% [3] - **4Q25 Results**: - Sales and NPAT grew by 27% and 134% YoY respectively [3] - The snack segment reported RMB 14.7 billion in sales and RMB 840 million in core NPAT with a net margin of 5.7% [1] Future Projections - **2026 Estimates**: - NPAT is expected to reach RMB 2.202 billion, with a 5% increase from previous estimates [14] - Sales are projected to grow at a CAGR of 23% from 2025 to 2027 [16] - Price Objective (PO) raised by 4% to RMB 275, based on a blend of P/E and DCF valuations [15][24] - **Store Expansion**: - Net openings of 2,949 stores in 2H25, bringing total store count to 18,314 (+29% YoY) [2] - 41% of new stores in 2025 were outside core markets, indicating increased penetration in Central, South, and Northwest China [2] Investment Rationale - **Rating**: Buy - **Market Share**: Expected to gain significant market share due to structural advantages in cost, scale, supply chain, and brand strength [12] - **Growth Drivers**: Transition towards a value-oriented supermarket format is anticipated to enhance unit economics and store-opening potential [12] Financial Metrics - **Earnings Revisions**: - 2026E EPS increased to RMB 11.51, reflecting higher margin estimates [14] - 2027E EPS adjusted to RMB 14.47 [14] - **Valuation Metrics**: - P/E ratio projected to decrease from 26.30x in 2025 to 16.69x in 2026 [4] - Dividend per share expected to rise from RMB 1.49 in 2025 to RMB 2.88 in 2026 [4] Risks and Considerations - **Downside Risks**: - Competition, slower-than-expected store expansion, declines in store unit economics, rising selling expenses, and tepid buyback of minority interest [24] Additional Insights - **Cash Flow**: - Free Cash Flow expected to grow from RMB 3.554 billion in 2025 to RMB 3.717 billion in 2026 [22] - **Balance Sheet Health**: - Net Debt to Equity ratio projected to improve significantly, indicating a strong balance sheet [23] This summary encapsulates the key points from the conference call regarding Wanchen Group's performance, future outlook, and investment rationale, providing a comprehensive overview for potential investors.

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of FUJIAN WANCHEN BIOTECHNOLOGY GROUP CO., LTD. 福建萬辰生物科技集團股份有限公司 (the "Company") (A joint stock company incorporated i ...